anti-Secretogranin III (SCG3) Antibodies

Human Secretogranin III (SCG3) interaction partners

1. SCG3 may be involved in PQinduced astrocyte activation via regulation of the expression and selective recruitment of cellular factors, thus suggesting that SCG3 may represent an indicator of astrocyte activation.

2. This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as "selective angiogenesis blockers" for targeted therapy of diabetic retinopathy. [review]

3. results suggested an association between the fucosylated glycoform of short-form SgIII and Small Cell Lung Carcinoma

4. HBXIP facilitates the proliferation of hepatoma cells by up-regulating SCG3 via E2F1 and miR-509-3p modulation.

5. SCG3 is essential in the process and targeting of neuropeptides and neurotrophins, its participation in the pathological progression of Alzheimer's disease may be suggested

6. SCG3 may be involved in apoptosis signal transduction as a caspase substrate.It may be a pivotal component of the neuroendocrine pathway & play an important role in neuronal communication & neurotransmitter release.

7. Our data suggest that genetic variations in the FTO, SCG3 and MTMR9 genes independently influence the risk of metabolic syndrome.

8. This short review deals with investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III.

9. SgIII was expressed in 41 of 47 neuroendocrine tumours. The expression of SgIII agreed well with that of CgA, CgB and SgII, with exceptions of phaeochromocytomas and parathyroid adenomas.

10. Genetic variations in the SCG3 gene may influence the risk of obesity through possible regulation of hypothalamic neuropeptide secretion.

11. Secretogranins III assays failed to detect increased concentrations in any of the patients with neuroendocrine tumours.

12. these data suggest that SgIII, DMT-1 and HNP-1 are implicated in cell-mediated LDL oxidation.

Mouse (Murine) Secretogranin III (SCG3) interaction partners

1. This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as "selective angiogenesis blockers" for targeted therapy of diabetic retinopathy.[ review]

2. we show by RNA silencing that CPE and SgIII play a synergistic role in the trafficking of POMC to granules of the regulated secretory pathway in AtT20 cells

3. SgIII knockdown impairs intracellular retention of chromogranin A and proopiomelanocortin in AtT-20 cells.

4. The robust expression of SgIII in astrocytes and its regulation in the injured brain suggest both intracellular and extracellular roles for this glial granin in the physiology and repair/damage of neuronal circuits.

5. SgIII directly binds to cholesterol components of the secretory granule membrane and targets chromogranin A to secretory granules in pituitary and pancreatic endocrine cells

6. SgIII and CPE form the separate functional sorting complex by anchoring to cholesterol-rich SG membranes, and POMC-derived peptides are transferred from CPE to SgIII, and subsequently to CgA.

7. SCG2, as well as SCG3, may be a potential regulator of food intake based on its capacity to accumulate appetite-related hormones into secretory granules.